AzTrials
AzTrials

Q FeverCARYANANCT07808775

Assessment of the Risk of Zoonotic Infections in Prisons in French Guiana

An observational study of Q Fever and Leptospirosis, run by Centre Hospitalier de Cayenne at 1 site in French Guiana.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The prison system in French Guiana is characterized by severe overcrowding, high levels of promiscuity, poor sanitary conditions, and the documented presence of potential reservoirs or vectors of zoonotic diseases, particularly swallows and rodents. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Q Fever, Leptospirosis, Chagas Disease
How many people
450 participants
Where
1 siteFrench Guiana
Study dates
1 Oct 2026to Oct 2028
How long will I take part?
12 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adults above 18 years old, incarcerated and housed at the French Guiana Correctional Facility for 15 days or less, from september 2026 to september 2028

Who may be able to join

  • Adult aged 18 or older
  • Incarcerated and housed at the French Guiana Correctional Facility for 15 days or less.

Who cannot join

  • Refusing to participate in the study
  • Pregnant women
  • Had already participated in the study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

French Guiana1 site
  • Centre Hospitalier de Cayenne

    Cayenne, French Guiana, 97300

    Timothée Bonifay, MD, +33594395050, timothee.bonifay@chu-guyane.fr

    Estelle Thomas, MPH, +33594395050, drci.promotion-cay@chu-guyane.fr

Other trials in French Guiana

About this study

The prison system in French Guiana is characterized by severe overcrowding, high levels of promiscuity, poor sanitary conditions, and the documented presence of potential reservoirs or vectors of zoonotic diseases, particularly swallows and rodents.

In French Guiana, several zoonotic diseases have a high incidence or are of particular public health significance, including Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis. Despite this context, the risk of zoonotic diseases in prisons remains poorly documented, even though endemic and epidemic circulation of Q fever has already been described at the French Guiana correctional facility. This study aims to document this risk in a systematic and prospective manner.

Read more

The main objective is to assess the prevalence of zoonotic infections (Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis) among inmates at the French Guiana Correctional Facility in 2026-2027.

The other objectives are :

  • To measure the seroprevalence of zoonotic infections among new arrivals at the French Guiana correctional facility;
  • To identify individual risk factors, both within and outside the prison, for acquiring zoonotic infections;
  • To analyze the results in relation to bioclimatic data (wind direction, humidity, precipitation, temperature) The expected benefits will aim to objectively assess the risk of zoonotic diseases within the French Guiana correctional facility, to improve understanding of zoonoses in prison settings, to guide the implementation of appropriate prevention and screening measures, and to contribute to improving health conditions in detention.

It should also strengthen cooperation between health and justice officials as part of an integrated approach to the prevention and management of infectious diseases.

Read the detailed description

The French Guiana Correctional Facility The French Guiana Correctional Facility (CPG) comprises a pretrial detention center characterized by a high turnover of inmates, a detention center, as well as a women's wing, a juvenile wing, and a day-release wing. The prison's theoretical capacity is 616 inmates, but chronic overcrowding is a serious problem, with the number of inmates reaching 1,050 in 2023-170% of its capacity. In 2023, the CPG recorded 1,750 inmates, including 121 women (11.5%)-more than the national average (around 4%). In total, 65% of the inmates were first-time offenders; the average age was 34, and more than half were French nationals. Approximately one-third of the inmates were serving sentences of less than 3 months.

Health care for inmates is part of a health care system that addresses all health issues, whether physical or psychiatric. The reform of the prison healthcare system entrusted the public hospital system with the responsibility for all such care. This care is governed by a methodological guide.

The CPG's Outpatient Consultation and Care Unit (UCSA) is responsible for addressing somatic issues, while the Incarceration Psychiatry Functional Unit (UFPI) handles psychological and psychiatric care. All incarcerated patients receive a routine initial medical examination (VME) within 48 hours of admission to custody, which includes a physical and psychological evaluation. One of the objectives of the VME is to detect any contagious or progressive conditions and to implement appropriate health measures. The inmate is evaluated both physically and psychologically. A clinical examination is performed. Following the consultation, specific treatment is recommended. An STI screening and a frontal chest X-ray are routinely offered, though they are not mandatory. The screening includes serology for syphilis, HIV, hepatitis B, hepatitis C, and HTLV, as well as urinary PCR tests for chlamydia and gonorrhea. The care pathway for detainees is well-structured, and they may also receive medical or paramedical consultations throughout their detention, with the wait time for a consultation depending on the level of urgency. In case of an emergency, the detainee may be transferred to the emergency medical department at the Cayenne Hospital. A routine annual checkup is offered.

The inmate population at the CPG is a vulnerable group facing a multitude of risk factors. Half of the prison population is French citizens originally from French Guiana. Furthermore, French Guiana is one of the French regions most affected by poverty; according to the national institute for statistics, 50% of the population lived below the poverty line in 2017. Compounding the issue of precarious living conditions are difficulties in accessing rights and healthcare. Nearly 30% of patients were undocumented prior to incarceration and were not entitled to outpatient care. Little data is available regarding educational attainment, but in 2020, 80.9% of inmates were referred by the prison administration to undergo an illiteracy assessment conducted by teachers. Precarious living conditions, low socioeconomic status, low educational attainment, and difficulties accessing healthcare and rights are recognized factors contributing to poor health. In addition to these pre-incarceration vulnerabilities, there are difficult conditions of detention, such as overcrowding exacerbated by prison overcrowding.

In terms of health and infectious disease risks, there is a high prevalence of people living with HIV (PLHIV), at 3.8% in 2021, representing approximately 3% of PLHIV under care in French Guiana in 2021. Following an analysis of tuberculosis-related risk, it was found that nearly 10% of people who reported having active tuberculosis between 2008 and 2020 in French Guiana had been incarcerated at least once.

Zoonotic risk In 2010, the prison administration commissioned an agency to assess the health risks associated with the presence of tens of thousands of swallows at the CPG. In fact, since the early 2000s, a colony of swallows has chosen the CPG as its roosting site. Their presence at the prison varies in size depending on the season. These swallows migrate to Argentina or southern Brazil starting in October to nest there and return to French Guiana to spend the southern hemisphere winter between April and May. A census conducted by the French Guiana Bird Study and Protection Group in July 2009 recorded 52,367 birds, more than 98% of which were Chalybea swallows. From October to April, when the bulk of the colony migrates south, some so-called "sedentary" swallows nevertheless remain in the vicinity of and within the prison grounds. Over the past ten years, this colony of "sedentary" birds has grown to its current size of approximately 15,000 to 25,000 birds. Numerous measures have been taken to scare the swallows away or relocate them, and the CPG has enlisted the help of experts to implement these measures.

These measures-which are by no means exhaustive-included installing protective nets, using gunshots to scare them away, setting up electric wires and ultrasonic devices, deploying inflatable scarecrows (shaped like falcons), using gas cannons and repellents, and constructing a structure adjacent to the CPG in an attempt to relocate them.

Overall, these various measures have been unsuccessful, but there appear to be fewer swallows each year (approximately 25,000 during the 2020 season). The agency report highlighted the zoonotic risk and conducted a theoretical assessment of these risks (in addition to an assessment of noise and odor nuisances). Four zoonoses were identified and considered to pose a risk of transmission within the prison: Chlamydia psittaci infections, toxoplasmosis, histoplasmosis, and Q fever.

Few studies on the health of incarcerated individuals have been conducted at the correctional facility; one study was reportedly carried out in the early 2000s by the Pasteur Institute of French Guiana, but the results were never published, and as a result, little information is available. It appears that rodents were captured, but no cases of Q fever were detected. No swallows or bats were captured. The presence of these animals has been confirmed, as they are potential reservoirs and/or intermediate hosts of zoonoses. The zoonotic risk is real but currently poorly understood. To date, although little data is available regarding zoonotic risks, given the high risk in the general population, these risks must be taken into account among the prison population in French Guiana.

Zoonoses are a major public health issue in French Guiana. They encompass a wide range of infections: bacterial (Q fever, leptospirosis), viral (rabies), parasitic (Chagas disease, toxoplasmosis, leishmaniasis), and fungal (histoplasmosis). These infections are responsible for a large number of hospitalizations and deaths, both during epidemics (such as leptospirosis) and in routine clinical practice (Q fever accounts for 30% of hospitalizations for pneumonia in the territory).

Although it is supposed to be isolated from the outside world, the CPG does not appear to be spared from these zoonotic diseases. There appear to be factors facilitating the transmission of zoonotic diseases-such as vectors and animal reservoirs-combined with overcrowding, and a lack of air conditioning. An endemic-epidemic circulation of Q fever within the CPG has recently been described. The incidence rate of acute, symptomatic Q fever even exceeded that of the general population in 2020. Other zoonotic diseases may be circulating within the CPG, as noted in the health risk assessment report by the agency (2010). The presence of rodents and swallows at the CPG could facilitate the spread of psittacosis (Chlamydia psittaci infection), Q fever, or histoplasmosis, although this hypothesis has not yet been verified.

Five zoonoses of interest were selected for this study :

  • Q fever
  • Leptospirosis
  • Chagas disease
  • Histoplasmosis
  • Toxoplamosis

Study hypothesis We hypothesize that there is a risk of zoonotic disease transmission at the French Guiana Penitentiary Center (CPG). This study aims to assess the actual zoonotic risk among the CPG prison population in a systematic, comprehensive, and multidisciplinary manner. Five zoonoses of interest were selected based on their transmission cycle (presence of potential reservoirs or vectors within the prison) and their epidemiological characteristics.

Expected benefits

This study will make it possible to:

  • Objectively assess the risk of zoonotic diseases within the French Guiana correctional facility
  • Implement preventive, informational, or reassurance measures based on the results obtained.
  • Increase knowledge about zoonotic diseases in correctional settings.
  • Raise awareness among correctional staff and relevant authorities regarding the importance of health in correctional facilities.
  • Contribute to improving the health and living conditions of inmates.
  • Strengthen cooperation between health and justice stakeholders to foster an integrated approach to the prevention and management of infectious diseases in correctional facilities.
Keywords
French Guiana, Prison health, zoonotic infections, correctional facility, cohort study
Medical subject headings
Q Fever, Leptospirosis, Chagas Disease, Histoplasmosis, Zoonoses

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07808775
Study groupRoleWhat they receive
Cohort participantsAdults aged more than 18, in retention since at least 15 days in the French Guiana correctional facility in Cayenne

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence rate of zoonotic infections of interest (Q fever, leptospirosis, Chagas disease, histoplasmosis, toxoplasmosis) among participants who were seronegative for the infection in question at enrollment

    Number of new infections documented during follow-up divided by the person-time actually observed in detention at the correctional facility, from enrollment until the occurrence of the event, the last available visit, release, transfer, withdrawal of consent, or the end of follow-up at 12 months.

    Measured: Baseline, Month 4, Month 8, Month 12

Secondary outcomes (10)
  1. Seroprevalence of Q fever at baseline

    Proportion of participants with positive Q fever serology at enrollment

    Measured: At Baseline

  2. Seroprevalence of leptospirosis at baseline

    Proportion of participants with positive Q leptospirosis serology at enrollment

    Measured: At Baseline

  3. Seroprevalence of Chagas disease at baseline

    Proportion of participants with positive Chagas disease serology at enrollment

    Measured: At Baseline

  4. Seroprevalence of toxoplasmosis at baseline

    Proportion of participants with positive toxoplasmosis serology at enrollment

    Measured: At Baseline

  5. Risk factors for Q fever infection both inside and outside prison

    Association between exposure and the occurrence of Q fever, whether inside or outside prison

    Measured: At Baseline, Month 4, Month 8 and Month 12

  6. Risk factors for leptospirosis infection both inside and outside prison

    Association between exposure and the occurrence of a lepstospirosis infection, whether inside or outside prison

    Measured: At Baseline, Month 4, Month 8 and Month 12

  7. Risk factors of Chagas disease infection both inside and outside prison

    Association between exposure and the occurrence of the Chagas disease, whether inside or outside prison

    Measured: At Baseline, Month 4, Month 8 and Month 12

  8. Risk factors of histoplasmosis infection both inside and outside prison

    Association between exposure and the occurrence of histoplasmosis infection, whether inside or outside prison

    Measured: At Baseline, Month 4, Month 8 and Month 12

  9. Risk factors of toxoplamosis infection both inside and outside prison

    Association between exposure and the occurrence of toxoplamosis infection, whether inside or outside prison

    Measured: At Baseline, Month 4, Month 8 and Month 12

  10. Influence of bioclimatic parameters

    Associations between bioclimatic parameters and incident infections, including, in particular, meteorological data (precipitation, humidity, temperature, wind direction)

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completionOct 2028 (estimated)
  4. Study completionOct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
450 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07808775
Sponsor's protocol ID
CARYANA
Acronym
CARYANA
Status last verified
Oct 2026
First submitted
2 Sep 2026
Last updated
19 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Only aggregated data will be shared through scientific production

Publications

  • Le Turnier P, Mosnier E, Schaub R, Bourhy P, Jolivet A, Cropet C, Villemant N, Trombert-Paolantoni S, Berlioz-Arthaud A, Nacher M, Demar M, Picardeau M, Djossou F, Epelboin L. Epidemiology of Human Leptospirosis in French Guiana (2007-2014): A Retrospective Study. Am J Trop Med Hyg. 2018 Sep;99(3):590-596. doi: 10.4269/ajtmh.17-0734. Epub 2018 Jul 19.

    PubMed 30039781
  • Thill P, Eldin C, Dahuron L, Berlioz-Artaud A, Demar M, Nacher M, Beillard E, Djossou F, Epelboin L. High endemicity of Q fever in French Guiana: A cross sectional study (2007-2017). PLoS Negl Trop Dis. 2022 May 18;16(5):e0010349. doi: 10.1371/journal.pntd.0010349. eCollection 2022 May.

    PubMed 35584144
  • Bonifay T, Beillard E, Daniel M, Schiemsky V, Vierendeels E, Demar M, Pastre A, Hamiche K, Nacher M, Epelboin L. High incidence of acute Q fever among incarcerated people in Cayenne, French Guiana. Rev Inst Med Trop Sao Paulo. 2022 Jun 10;64:e42. doi: 10.1590/S1678-9946202264042. eCollection 2022.

    PubMed 35703611
  • Epelboin L, Chesnais C, Boulle C, Drogoul AS, Raoult D, Djossou F, Mahamat A. Q fever pneumonia in French Guiana: prevalence, risk factors, and prognostic score. Clin Infect Dis. 2012 Jul;55(1):67-74. doi: 10.1093/cid/cis288. Epub 2012 Mar 22.

    PubMed 22441648
  • Jolivet A, Cadot E, Florence S, Lesieur S, Lebas J, Chauvin P. Migrant health in French Guiana: are undocumented immigrants more vulnerable? BMC Public Health. 2012 Jan 19;12:53. doi: 10.1186/1471-2458-12-53.

    PubMed 22260085
  • Huber F, Vandentorren S, Merceron A, Bonifay T, Pastre A, Lucarelli A, Nacher M. Returning to care after incarceration with HIV: the French Guianese experience. BMC Public Health. 2020 May 24;20(1):754. doi: 10.1186/s12889-020-08772-9.

    PubMed 32448209
  • Huber F, Vandentorren S, Merceron A, Chaponnay A, Gadio G, About V, Pastre A, Nacher M. HIV-positive in the darkness of a correctional facility: more vulnerable and less treated. Int J STD AIDS. 2019 Apr;30(5):460-466. doi: 10.1177/0956462418816452. Epub 2019 Jan 10.

    PubMed 30630398

Questions about this trial

What is this clinical trial studying?

An observational study of Q Fever and Leptospirosis, run by Centre Hospitalier de Cayenne at 1 site in French Guiana.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in French Guiana. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Timothée Bonifay, MD (+33594395050, timothee.bonifay@chu-guyane.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence rate of zoonotic infections of interest (Q fever, leptospirosis, Chagas disease, histoplasmosis, toxoplasmosis) among participants who were seronegative for the infection in question at enrollment (time frame: Baseline, Month 4, Month 8, Month 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07808775, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in